Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

Omnipod 5 is available with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (“CGM”) sensor compatibility. The latest development represents a significant step forward ...

Omnipod 5 is available with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (“CGM”) sensor compatibility. The latest development represents a significant ...

The FreeStyle Libre 3 system consists of the sensor around the size of a £1 coin that is worn on the upper arm and an app which can be used by users to record their real-time glucose levels and ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Sayer previewed other upcoming features for Dexcom’s CGMs, including plans to launch a 15-day sensor in the second half of the year. Competitor Abbott currently has 15-day sensors with its Freestyle ...

The company plans to pursue an expanded indication for iLet for people with Type 2 diabetes who take insulin ... Beta Bionics has integrated iLet with Abbott’s latest Freestyle Libre glucose sensor, ...